[English] 日本語
Yorodumi- PDB-8vrb: Structure of a synthetic antibody in complex with a class I MHC p... -
+
Open data
-
Basic information
| Entry | Database: PDB / ID: 8vrb | ||||||
|---|---|---|---|---|---|---|---|
| Title | Structure of a synthetic antibody in complex with a class I MHC presenting a hapten-peptide conjugate | ||||||
Components |
| ||||||
Keywords | IMMUNE SYSTEM / Complex / Synthetic antibody / MHC class I / covalently modified peptide | ||||||
| Function / homology | Function and homology informationantigen processing and presentation of peptide antigen via MHC class I / response to mineralocorticoid / GMP binding / LRR domain binding / response to gravity / myoblast proliferation / cardiac muscle cell proliferation / Signaling by RAS GAP mutants / Signaling by RAS GTPase mutants / Activation of RAS in B cells ...antigen processing and presentation of peptide antigen via MHC class I / response to mineralocorticoid / GMP binding / LRR domain binding / response to gravity / myoblast proliferation / cardiac muscle cell proliferation / Signaling by RAS GAP mutants / Signaling by RAS GTPase mutants / Activation of RAS in B cells / GTPase complex / RAS signaling downstream of NF1 loss-of-function variants / RUNX3 regulates p14-ARF / protein phosphatase type 1 complex / SOS-mediated signalling / Activated NTRK3 signals through RAS / Activated NTRK2 signals through RAS / SHC1 events in ERBB4 signaling / Signalling to RAS / negative regulation of programmed cell death / serine/threonine protein kinase complex / SHC-related events triggered by IGF1R / Activated NTRK2 signals through FRS2 and FRS3 / Estrogen-stimulated signaling through PRKCZ / SHC-mediated cascade:FGFR3 / MET activates RAS signaling / positive regulation of Ras protein signal transduction / response to isolation stress / SHC-mediated cascade:FGFR2 / SHC-mediated cascade:FGFR4 / PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases / Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants / Signaling by PDGFRA extracellular domain mutants / Erythropoietin activates RAS / SHC-mediated cascade:FGFR1 / Signaling by FGFR4 in disease / Signaling by CSF3 (G-CSF) / FRS-mediated FGFR3 signaling / Signaling by FLT3 ITD and TKD mutants / FRS-mediated FGFR2 signaling / FRS-mediated FGFR4 signaling / p38MAPK events / FRS-mediated FGFR1 signaling / Signaling by FGFR3 in disease / Tie2 Signaling / Signaling by FGFR2 in disease / GRB2 events in EGFR signaling / Signaling by FLT3 fusion proteins / SHC1 events in EGFR signaling / FLT3 Signaling / EGFR Transactivation by Gastrin / Signaling by FGFR1 in disease / NCAM signaling for neurite out-growth / liver development / CD209 (DC-SIGN) signaling / positive regulation of TOR signaling / GRB2 events in ERBB2 signaling / Downstream signal transduction / response to glucocorticoid / Insulin receptor signalling cascade / SHC1 events in ERBB2 signaling / regulation of natural killer cell mediated immunity / early endosome lumen / Nef mediated downregulation of MHC class I complex cell surface expression / DAP12 interactions / Constitutive Signaling by Overexpressed ERBB2 / Ras activation upon Ca2+ influx through NMDA receptor / Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants / Endosomal/Vacuolar pathway / canonical NF-kappaB signal transduction / VEGFR2 mediated cell proliferation / small monomeric GTPase / Antigen Presentation: Folding, assembly and peptide loading of class I MHC / endomembrane system / FCERI mediated MAPK activation / lumenal side of endoplasmic reticulum membrane / female pregnancy / regulation of iron ion transport / negative regulation of iron ion transport / negative regulation of forebrain neuron differentiation / antigen processing and presentation of exogenous peptide antigen via MHC class Ib / MHC class Ib protein complex / peptide antigen assembly with MHC class I protein complex / ER to Golgi transport vesicle membrane / Signaling by ERBB2 TMD/JMD mutants / HFE-transferrin receptor complex / MHC class I peptide loading complex / transferrin transport / negative regulation of receptor-mediated endocytosis / cellular response to iron ion / positive regulation of T cell cytokine production / Constitutive Signaling by EGFRvIII / antigen processing and presentation of endogenous peptide antigen via MHC class I / Signaling by SCF-KIT / RAF activation / Signaling by high-kinase activity BRAF mutants / Signaling by ERBB2 ECD mutants / peptide antigen assembly with MHC class II protein complex / MHC class I protein complex / MAP2K and MAPK activation Similarity search - Function | ||||||
| Biological species | Homo sapiens (human) | ||||||
| Method | ELECTRON MICROSCOPY / single particle reconstruction / cryo EM / Resolution: 3.25 Å | ||||||
Authors | Maso, L. / Bang, I. / Koide, S. | ||||||
| Funding support | United States, 1items
| ||||||
Citation | Journal: Proc Natl Acad Sci U S A / Year: 2024Title: Molecular basis for antibody recognition of multiple drug-peptide/MHC complexes. Authors: Lorenzo Maso / Epsa Rajak / Injin Bang / Akiko Koide / Takamitsu Hattori / Benjamin G Neel / Shohei Koide / ![]() Abstract: The HapImmune platform exploits covalent inhibitors as haptens for creating major histocompatibility complex (MHC)-presented tumor-specific neoantigens by design, combining targeted therapies with ...The HapImmune platform exploits covalent inhibitors as haptens for creating major histocompatibility complex (MHC)-presented tumor-specific neoantigens by design, combining targeted therapies with immunotherapy for the treatment of drug-resistant cancers. A HapImmune antibody, R023, recognizes multiple sotorasib-conjugated KRAS(G12C) peptides presented by different human leukocyte antigens (HLAs). This high specificity to sotorasib, coupled with broad HLA-binding capability, enables such antibodies, when reformatted as T cell engagers, to potently and selectively kill sotorasib-resistant KRAS(G12C) cancer cells expressing different HLAs upon sotorasib treatment. The loosening of HLA restriction could increase the patient population that can benefit from this therapeutic approach. To understand the molecular basis for its unconventional binding capability, we used single-particle cryogenic electron microscopy to determine the structures of R023 bound to multiple sotorasib-peptide conjugates presented by different HLAs. R023 forms a pocket for sotorasib between the V and V domains, binds HLAs in an unconventional, angled way, with V making most contacts with them, and makes few contacts with the peptide moieties. This binding mode enables the antibody to accommodate different hapten-peptide conjugates and to adjust its conformation to different HLAs presenting hapten-peptides. Deep mutational scanning validated the structures and revealed distinct levels of mutation tolerance by sotorasib- and HLA-binding residues. Together, our structural information and sequence landscape analysis reveal key features for achieving MHC-restricted recognition of multiple hapten-peptide antigens, which will inform the development of next-generation therapeutic antibodies. | ||||||
| History |
|
-
Structure visualization
| Structure viewer | Molecule: Molmil Jmol/JSmol |
|---|
-
Downloads & links
-
Download
| PDBx/mmCIF format | 8vrb.cif.gz | 125.5 KB | Display | PDBx/mmCIF format |
|---|---|---|---|---|
| PDB format | pdb8vrb.ent.gz | 92.8 KB | Display | PDB format |
| PDBx/mmJSON format | 8vrb.json.gz | Tree view | PDBx/mmJSON format | |
| Others | Other downloads |
-Validation report
| Arichive directory | https://data.pdbj.org/pub/pdb/validation_reports/vr/8vrb ftp://data.pdbj.org/pub/pdb/validation_reports/vr/8vrb | HTTPS FTP |
|---|
-Related structure data
| Related structure data | ![]() 43480MC ![]() 8vr9C ![]() 8vraC M: map data used to model this data C: citing same article ( |
|---|---|
| Similar structure data | Similarity search - Function & homology F&H Search |
-
Links
-
Assembly
| Deposited unit | ![]()
|
|---|---|
| 1 |
|
-
Components
-Protein , 2 types, 2 molecules AB
| #1: Protein | Mass: 31725.936 Da / Num. of mol.: 1 Source method: isolated from a genetically manipulated source Source: (gene. exp.) Homo sapiens (human) / Plasmid: pET28 / Production host: ![]() |
|---|---|
| #2: Protein | Mass: 11819.238 Da / Num. of mol.: 1 / Fragment: UNP residues 20-119 Source method: isolated from a genetically manipulated source Source: (gene. exp.) Homo sapiens (human) / Gene: B2M, CDABP0092, HDCMA22P / Plasmid: pET28 / Production host: ![]() |
-Antibody , 2 types, 2 molecules DE
| #4: Antibody | Mass: 23518.178 Da / Num. of mol.: 1 Source method: isolated from a genetically manipulated source Source: (gene. exp.) Homo sapiens (human) / Production host: ![]() |
|---|---|
| #5: Antibody | Mass: 24034.822 Da / Num. of mol.: 1 Source method: isolated from a genetically manipulated source Source: (gene. exp.) Homo sapiens (human) / Production host: ![]() |
-Protein/peptide / Non-polymers , 2 types, 2 molecules C

| #3: Protein/peptide | Mass: 889.094 Da / Num. of mol.: 1 / Fragment: residues 7-16 / Mutation: G12C / Source method: obtained synthetically / Details: Cys12 conjugated to covalent inhibitor sotorasib / Source: (synth.) Homo sapiens (human) / References: UniProt: P01116 |
|---|---|
| #6: Chemical | ChemComp-MOV / |
-Details
| Has ligand of interest | Y |
|---|---|
| Has protein modification | Y |
-Experimental details
-Experiment
| Experiment | Method: ELECTRON MICROSCOPY |
|---|---|
| EM experiment | Aggregation state: PARTICLE / 3D reconstruction method: single particle reconstruction |
-
Sample preparation
| Component |
| ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular weight | Value: 0.0929 MDa / Experimental value: NO | ||||||||||||||||||||||||||||||
| Source (natural) |
| ||||||||||||||||||||||||||||||
| Source (recombinant) |
| ||||||||||||||||||||||||||||||
| Buffer solution | pH: 7.4 | ||||||||||||||||||||||||||||||
| Buffer component |
| ||||||||||||||||||||||||||||||
| Specimen | Conc.: 2 mg/ml / Embedding applied: NO / Shadowing applied: NO / Staining applied: NO / Vitrification applied: YES | ||||||||||||||||||||||||||||||
| Specimen support | Grid material: GOLD / Grid mesh size: 300 divisions/in. / Grid type: Quantifoil R0.6/1 | ||||||||||||||||||||||||||||||
| Vitrification | Instrument: FEI VITROBOT MARK IV / Cryogen name: ETHANE / Humidity: 100 % / Chamber temperature: 277 K |
-
Electron microscopy imaging
| Experimental equipment | ![]() Model: Titan Krios / Image courtesy: FEI Company |
|---|---|
| Microscopy | Model: FEI TITAN KRIOS |
| Electron gun | Electron source: FIELD EMISSION GUN / Accelerating voltage: 300 kV / Illumination mode: FLOOD BEAM |
| Electron lens | Mode: BRIGHT FIELD / Nominal magnification: 105000 X / Nominal defocus max: 2400 nm / Nominal defocus min: 900 nm / Cs: 2.7 mm |
| Specimen holder | Cryogen: NITROGEN |
| Image recording | Average exposure time: 2 sec. / Electron dose: 57.56 e/Å2 / Film or detector model: GATAN K3 (6k x 4k) / Num. of grids imaged: 1 |
| EM imaging optics | Energyfilter slit width: 20 eV |
-
Processing
| EM software |
| ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTF correction | Type: PHASE FLIPPING AND AMPLITUDE CORRECTION | ||||||||||||||||
| 3D reconstruction | Resolution: 3.25 Å / Resolution method: FSC 0.143 CUT-OFF / Num. of particles: 90612 / Symmetry type: POINT |
Movie
Controller
About Yorodumi



Homo sapiens (human)
United States, 1items
Citation




PDBj
























FIELD EMISSION GUN